Incidence of Psoriatic Arthritis Among Psoriasis Patients Newly Initiated With Secukinumab in a US Claims Database and a UK Registry

Novartis

Status: Completed

Conditions: Psoriasis; Psoriatic Arthritis

Study type: Observational

Funder types: Industry

Identifiers

NCT06172426

CAIN457A2026

Details and patient eligibility

About

This was a retrospective cohort study to assess the incidence rate of psoriatic arthritis (PsA) among psoriasis (PsO) patients newly initiated on secukinumab or any biologics/apremilast (small molecule). The analysis was performed in two databases, IBM® MarketScan® database: Commercial Claims and Encounters (CCAE) and Medicare Supplemental Beneficiaries (MDCR) from 01 January 2010 to 30 June 2021 and BADBIR from 01 January 2016 to 01 September 2021.

Enrollment: 1,171 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

MarketScan® secukinumab cohort:

Inclusion criteria:

• Included patients with at least 1 secukinumab claim between 01 January 2015 and 30 June 2020 (index date is the first secukinumab claim)
• Included patients age ≥18 years as of the year of index date
• Included patients with at least 1 non-ruleout psoriasis diagnosis during 2 years of pre-index period
• Included patients with continuous medical/pharmacy coverage in the 2-year pre-index period
• Included patients with continuous medical/pharmacy coverage in the 1-year post-index period

Exclusion criteria:

• Excluded patients with any psoriatic arthritis diagnosis during 2 years to 5 years pre-index period, as well as on the index date
• Excluded patients with any biologics/apremilast including secukinumab claim during the 2-year pre-index (excluding index date)
• Excluded patients received other non-secukinumab biologics/apremilast during 6 months post index date period (including index date) (This criterion is only applicable for the secukinumab cohort)

BADBIR cohort:

Inclusion criteria:

• Included non-switched patients with secukinumab treatment on or after the enrollment between 01 January 2017 to 01 September 2020

  • Non-switched patients are those who did not use other biologics/apremilast treatments on the enrollment date
  • Index date will be the date of the first secukinumab treatment date

• Included patients with age ≥ 18 on the index date

• Included patients with psoriasis diagnosis in the pre-index period and index date

• Included patients with ≥ 1 year follow-up period

  • Follow-up period is the gap between patient's last visit date and index date

Exclusion criteria:

• Excluded patients with psoriatic arthritis (PsA) prior to and on index date
• Excluded patients with any biologics/apremilast including secukinumab in the baseline period

Trial design

1,171 participants in 2 patient groups

MarketScan® secukinumab, other biologics/apremilast, and any biologics/apremilast cohort

BADBIR secukinumab cohort